Global CAR T-Cell Therapy Market: By indication (Leukemia, Lymphoma, and Myeloma); Source (Autologous and Allogenic); Type of Therapy (Monotherapy and Combination Therapy); Product (ABECMA, Breyanzi, Carvykti, Kymriah, Tecartus, and Yescarta); Administration Setting (Inpatient and Outpatient); Region—Market Forecast and Analysis for 2024-2032
The global CAR T-Cell Therapy Market is projected to reach more than USD 22.2 billion by 2032 from USD 2.1 billion in 2023, growing at a CAGR of 30% from 2024-2032. Read More
We Are Trusted By These Great Companies!
- Published On: 02-Mar-2024 | Format:
![pdf]()
![powerpoint]()
![excel]()
| Report ID: AA0324792
| Report ID: AA0324792Ask For Customization
Base Year 2023
Historic Year 2019-2022
Forecast Year 2024-2032
No Of Pages 225
Total Figures 100
Total Tables 90
Features | Type of License | |||
 Single User |   Multi User |  Corporate | ||
| e-Access | ✓ | ✓ | ✓ | |
User Sharing | 1 User Only | 2-6 Users | Unlimited within Company/Enterprise | |
⨉ | ⨉ | ✓ | ||
Free Customization | Up To 30 hrs work | Up To 60 hrs work | Up To 80 hrs work | |
Deliverable |
| ✓ | ✓ | ✓ |
| ⨉ | ✓ | ✓ | |
| ⨉ | ⨉ | ✓ | |
Analyst Support | 4 Month Post purchase | 7 Month Post purchase | One Year Post purchase | |
Free Report update in next update cycle | ⨉ | ⨉ | ✓ | |
Free Industry Update (Within 180 days) | ⨉ | ⨉ | ✓ | |
Benefit | Up to 20% off on next purchase | Up to 30% off on next purchase | Up to 40% off on next purchase | |
